**Title:** The First Modified Delphi Consensus Statement on Sleeve Gastrectomy

**Short Title:** Delphi Consensus on Sleeve Gastrectomy

**Authors:**

|  |  |
| --- | --- |
| Kamal K Mahawar, MS, MSc, FRCSEd 1,2 |  |
| Islam Omar, MB BCh, MSc, MRCS, FEBS/GenSurg 1 |  |
| Rishi Singhal, MD, FRCS 3 |  |
| Sandeep Aggarwal, MBBS, MS, FACS 4 |  |
| Mustafa Ismail Allouch, MD 5 |  |
| Salman K Alsabah, MD, MBA, FRCSC, FACS 6 |  |
| Luigi Angrisani, MD 7 |  |
| Faruq Mohamed Badiuddin, MBBS, MS, FRCS 8 |  |
| Jose María Balibrea, MD, PhD 9 |  |
| Ahmad Bashir, MD, DABS, FACS, FASMBS 10 |  |
| Estuardo Behrens, MD, MACG, FACS, FICS, FASMBS 11 |  |
| Kiron Bhatia, MBBS, MMedSci(Surg), FRACS 12 |  |
| Laurent Biertho, MD 13 |  |
| L Ulas Biter, MD, FDCS, FDSMBS 14 |  |
| Jerome Dargent, MD 15 |  |
| Maurizio De Luca, MD, PhD 16 |  |
| Eric DeMaria, MD, FACS, FASMBS 17 |  |
| Mohamed Hayssam Elfawal, MD, FACS, IFASMBS 18 |  |
| Martin Fried, MD, PhD 19 |  |
| Khaled A Gawdat, MD 20 |  |
| Yitka Graham, PhD, BSc, FTO S, C Mgr 1,2 |  |
| Miguel F Herrera, MD 21 |  |
| Jacques M Himpens, MD 22 |  |
| Farah A Hussain, MD, FACS, FASMBS 23 |  |
| Kazunori Kasama, MD, FACS 24 |  |
| David Kerrigan, MD 25 |  |
| Lilian Kow, BMBS, PhD, FRACS 26 |  |
| Jon Kristinsson, MD, PhD 27 |  |
| Marina Kurian, MD 28 |  |
| Ronald Liem, MD 29 |  |
| Rami Edward Lutfi, MD, FACS, FASMBS 30 |  |
| Vinod Menon, MD 31 |  |
| Karl Miller, MD 32 |  |
| Patrick Noel, MD, DACS, FASMBS 33, 34 |  |
| Oral Ospanov, MD, PhD, DmedSc 35 |  |
| Mahir M Ozmen, MD, MS, FACS, FRCS, FEBS, FASMS 36 |  |
| Ralph Peterli, MD 37 |  |
| Jaime Ponce, MD, FACS, FASMBS 38 |  |
| Gerhard Prager, MD 39 |  |
| Arun Prasad, FRCS, FRCSEd, FACS, MS (MAMC), MBBS (AFMC) 40 |  |
| P Praveen Raj, MS, DNB, DNB(SGE), FACS, PhD 41 |  |
| Nelson R Rodriguez, MD 42 |  |
| Raul Rosenthal, MD, FACS, FASMBS 43 |  |
| Nasser Sakran, MD, BCs, FISA 44 |  |
| Jorge Nunes Santos, MD, PhD, FACS 45 |  |
| Asim Shabbir, MBBS, FRCS 46 |  |
| Scott A Shikora, MD, FACS 47 |  |
| Peter K Small, MB ChB, MD, FRCS 1,2 |  |
| Craig J Taylor, MD 48 |  |
| Cunchuan Wang, MD, PhD 49 |  |
| Rudolf Alfred Weiner, MD 50 |  |
| Mariusz Wylezol, MD, PhD 51 |  |
| Wah Yang, MD 49 |  |
| Ali Aminian, MD, FACS, FASMBS 52 |  |

**Department and Institute:**

|  |
| --- |
| 1. Bariatric Unit, South Tyneside and Sunderland NHS Trust, Sunderland, United Kingdom |
| 2. Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, United Kingdom |
| 3. Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, United Kingdom |
| |  | | --- | | 4. All India Institute of Medical Sciences (AIIMS), New Delhi, India | | 5. Nini Hospital, Lebanon | | 6. Kuwait university, Kuwait | | 7. University of Naples, Italy | | 8. Valiant clinic, Dubai, United Arab Emirates | | 9. Hospital Clínic de Barcelona, Spain | | 10. GBMC at Jordan Hospital, Jordan | | 11. New Life Center, Guatemala | | 12. Austin Health, Melbourne, Australia | | 13. Quebec Heart and Lung Institute - Laval University, Canada | | 14.Franciscus Gasthuis Rotterdam, Netherlands | | 15. Polyclinique Lyon Nord, France | | 16. Castelfranco Montebelluna Hospitals, Italy | | 17. East Carolina University, United States of America | | 18. Makassed General Hospital, Lebanon | | 19. OB klinika - Center for Treatment of Obesity and Metabolic Disorders, Prague, Czech Republic | | 20. Ain Shams School of Medicine, Egypt | |
| |  | | --- | | 21. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México | | 22. CHIREC Delta Hospital, Belgium | | 23. Oregon Health & Science University, United States of America | | 24. Yotsuya Medical Cube, Japan | | 25. Phoenix Health, United Kingdom | | 26. Flinders University, South Australia, Australia | | 27. Oslo University Hospital, Norway | | 28. New York University School of Medicine, United States of America | | 29. Dutch Obesity Clinic (NOK), The Hague, Netherlands | | 30. University of Illinois, Chicago, United States of America | | 31. University Hospitals Coventry & Warwickshire NHS Trust, United Kingdom | | 32. Diakonissen & Wehrle Private Hospital, Salzburg, Austria | | 33. Bouchard Private Hospital, Elsan, Marseille, France | | 34. Mediclinic Parkview, Dubai, United Arab Emirates  35. KF "University Medical Center", Kazakhstan | | 36. Istinye University, Turkey | | 37. University Hospital Basel, Switzerland | | 38 CHI Memorial Hospital, Chattanooga Tennessee, United States of America | | 39. Medical University of Vienna, Austria | | 40. Apollo Hospitals, New Delhi, India | | 41. Gem Hospital, India | | 42. Centro Médico Puerta de Hierro Andares, México | | 43. Cleveland Clinic, Florida, United States of America | | 44. Emek Medical Center, Afula, Israel | | 45. Jorge Manuel Nunes dos Santos, Portugal | | 46. National University Hospital, Singapore | | 47. Brigham and Women’s Hospital, Harvard Medical School, United States of America | | 48. Concord Repatriation General Hospital, Sydney, Australia | | 49. The first affiliated hospital of Jinan University, China | | 50. Department for Metabolic Surgery, Sana Klinikum Offenbach, Germany | | 51. Medical University of Warsaw, Poland |   52. Cleveland Clinic, United States of America |

**Author for Correspondence:**

* **Kamal K Mahawar**
* Consultant Surgeon

South Tyneside and Sunderland NHS Trust

Sunderland SR4 7TP, UK

* Email: [kmahawar@gmail.com](mailto:kmahawar@gmail.com)

**Key Words:** Bariatric Surgery, Obesity Surgery, Sleeve Gastrectomy, Gastric Sleeve, Consensus

**Source(s) of Funding:** None

**The First Modified Delphi Consensus Statement on Sleeve Gastrectomy**

**Abstract:**

**Introduction:** Sleeve Gastrectomy (SG) is the commonest bariatric procedure worldwide. Yet, there is significant variation in practice concerning its various aspects. This paper report results from the first modified Delphi consensus-building exercise on SG.

**Methods:** We established a committee of 54 globally recognized opinion-makers in this field. The committee agreed to vote on several statements concerning SG. An agreement or disagreement amongst ≥ 70.0% experts was construed as a consensus.

**Results:** The committee achieved a consensus of agreement (n=71) or disagreement (n=7) for 78 out of 97 proposed statements after two rounds of voting. The committee agreed with 96.3% consensus that the characterization of SG as a purely restrictive procedure was inaccurate and there was 88.7% consensus that SG was NOT a suitable standalone, primary, surgical weight loss option for patients with Barrett’s Esophagus (BE) without dysplasia. There was an overwhelming consensus of 92.5% that the Sleeve should be fashioned over an orogastric tube of 36-40 Fr and a 90.7% consensus that Surgeons should stay at least 1 cm away from the angle of His. Remarkably, the committee agreed with 81.1% consensus that SG patients should undergo a screening endoscopy every 5 years after surgery to screen for BE.

**Conclusion:** A multinational team of experts achieved consensus on several aspects of SG. The findings of this exercise should help improve the outcomes of SG, the commonest bariatric procedure worldwide, and guide future research on this topic.

**Key Words:** Bariatric Surgery, Obesity Surgery, Sleeve Gastrectomy, Gastric Sleeve

**The First Modified Delphi Consensus Statement on Sleeve Gastrectomy**

**Introduction:**

Sleeve Gastrectomy (SG) is now the most common bariatric procedure worldwide [1]. Few consensus statements have been published on this procedure, with the last one published in 2016 [2]. Despite these, significant variations in practices persist concerning various aspects of this procedure [3]. Developing robust evidence to identify the best choice from amongst a range of practices can be a time consuming and laborious process. This often leads to individual clinicians relying on authoritative and expert advice to base their clinical decisions on.

This is even though expert advice is graded as level 5 evidence which is the lowest level of quality of evidence, and the recommendations that can be issued from such evidence are graded as D, the lowest possible grade [4]. Not only this, the experts can themselves have opposed views, leaving room for confusion. Consensus building amongst experts can help reduce this confusion, and also somewhat improve the quality of the recommendations. This is probably why consensus-building exercises are now commonplace in a variety of clinical situations.

Delphi consensus-building approach was first developed by Olaf Helmer-Hirschberg and Norman Dalkey of the RAND (Research and Development) Corporation, an American non-profit think tank [5]. Modifications of this approach to consensus-building are increasingly replacing traditional protocols in all walks of medicine including bariatric surgery [6-7]. They are recognized to be more robust and cheaper compared to consensus building in an open room setting [8]. To the best of our knowledge, no attempt has been made to perform a consensus-building exercise using a modified Delphi protocol for SG.

The purpose of this study was to achieve consensus on a number of preoperative, intraoperative, and postoperative considerations concerning SG using a modified Delphi protocol.

**Methods:**

We constituted a committee (Supplemental data 1) of 54 recognized opinion-makers in the field of bariatric and metabolic surgery (from 32 countries) with a working knowledge of the English language and a special interest in SG. The committee members voted twice on several aspects of SG.

Members agreed on several statements to vote on after discussion amongst themselves. The voting for each round was only started when the whole committee was satisfied with the language of the statements to be voted on. The members were asked to either agree or disagree with each statement and were not given the choice to skip any. Following other published bariatric surgery consensus papers [4,5], an agreement amongst ≥ 70.0% of experts was regarded as consensus. Voting was conducted virtually on online survey platforms and no attempt was made to identify individual members’ responses.

The first-round voting link was made live on the 12th of January 2020 and the second-round voting was concluded on 22nd April 2020. The committee voted on 84 statements in the first round. In the second round, the committee voted on only those statements where there was an agreement/ disagreement of ≥ 60.0% but not enough to reach the consensus threshold of 70.0%. The committee did not vote on statements with an agreement/disagreement of < 60.0% in the first round as previous consensus-building exercises have shown that these statements rarely achieve consensus even after a second-round of voting [6-7]. The committee also introduced 13 new statements in the second round to further clarify some of the statements voted on in the first round.

**Statement of Informed Consent:** Not Applicable

**IRB Approval:** Not Applicable

**Results:**

A total of 54 SG recognized global bariatric surgery experts (Supplemental data 1)from 32 countries voted on a total of 97 statements concerning various aspects of SG.

**Table 1** presents the results of voting on some of the key preoperative considerations of SG. In total, there was a consensus of agreement on 28 of these statements and a consensus of disagreement on 6 statements. There was no consensus on 6 statements proposed. Out of six statements that the committee voted on again in the second round, four achieved a consensus in the second round. (Supplemental data 2)

**Table 2** presents the results of voting on key perioperative considerations of SG. The committee agreed with a consensus on 21 of the 26 statements voted on in this category. There was a consensus of disagreement on two statements and an inability to reach consensus on the remaining three. Both of the statements that the committee voted on again reached a consensus in the second round. (Supplemental data 3)

**Table 3** presents the results of voting on key postoperative considerations of SG. The committee achieved a consensus of agreement on six out of 13 statements voted on in this category. (Supplemental data 4).

**Table 4** presents the results on the management of complications and revisional bariatric surgery in the context of SG. There was a consensus of agreement on 16 out of 18 statements voted on in this category and that of disagreement on one statement. (Supplemental data 5)

In total, the committee agreed with a consensus on 71 out of the 97 proposed statements. There was a consensus of disagreement for seven proposed statements and no consensus was achieved for the remaining 19 statements.

**Discussion:**

The last consensus statement to be published on SG came out in 2016; and in recent years, there have been significant controversies on several preoperative, perioperative, and postoperative considerations involving this procedure. A recent survey [3] of 863 surgeons from 67 countries showed considerable variation in a range of practices concerning this procedure. Moreover, none of the previous consensus statements have appeared to follow a rigorous modified Delphi protocol. All these factors, coupled with the enormous popularity of SG, led us to embark on this modified Delphi consensus-building exercise on this procedure.

When it came to preoperative considerations, we attempted to challenge the traditional restrictive/malabsorptive paradigm by voting on the purported mechanisms of action of SG. The committee agreed with a significant consensus of 89.0% that SG works through yet incompletely understood neurohormonal mechanisms and an even higher 96.0 % felt that the characterization of SG as a purely restrictive procedure was inaccurate.

We then aimed to identify which group of patients SG was considered an option for. Unsurprisingly, the committee endorsed with consensus several clinical situations (Supplemental data 2) where SG could be considered an option. Remarkably, however, there was no consensus on whether SG was a suitable standalone, primary, surgical weight loss option for patients with BMI ≥ 60 kg/m2. There was further no consensus on SG being a suitable, primary, surgical weight loss option for appropriate patients with long-standing (> 5-year duration) Type 2 Diabetes Mellitus with a BMI of > 35 kg/m2. Given that we now know that a gastric bypass offers superior weight loss and metabolic outcomes in comparison to SG in the longer term for this population of patients [9], this may suggest that SG can be considered slightly less popular in those with a more significant metabolic burden, but still favored by a majority.

There is little doubt that a significant number of patients suffer from Gastro-Esophageal Reflux Disease (GERD) after SG, and that this number is higher than those undergoing RYGB [10]. This is probably why many surgeons regard the presence of GERD or Hiatal Hernia as contraindications for undergoing SG [3]. This explains why there was no consensus on performing SG on patients needing daily medication for GERD or >4.0 cm hiatal hernia. When it comes to Barrett’s Esophagus (BE), RYGB can lead to the remission of this condition in a large number of patients [11], while on the other hand, there has been data suggesting that some SG patients can develop BE in the long-term [12]. This may be why the committee rejected SG as an option for patients with BE with consensus; irrespective of the presence or absence of dysplasia, or the patient's willingness to undergo lifelong annual surveillance.

There has been much debate in the scientific literature regarding various technical aspects of SG with significant variation in practice [3,13]. It is, therefore, important that the committee agreed with a consensus of 85.0% that construction of the sleeve should start within 4-5 cm from the Pylorus to avoid leaving behind a large antrum and with 92.5% consensus that the sleeve should be fashioned over an orogastric tube of a size 36-40 Fr. The committee achieved a consensus that there was currently insufficient evidence to recommend routine use of staple line reinforcement with sutures (89%), staple line buttressing (81.5%), fibrin glue (100%), routine placement of band (96%), routine fundoplication as in Nissen-Sleeve (98%), or single incision sleeve (90%). This should not be viewed as a rejection of these approaches but simply a reminder for development of more evidence to clarify the advantages and disadvantages of each of them.

American Society for Metabolic and Bariatric Surgery recommends [14] that patients undergoing SG be routinely supplemented with iron, vitamin D, and calcium in dosages that are much higher than typical over the counter multivitamin/mineral supplements. It was, therefore, interesting that there was no consensus reached on routine supplementation for these in this exercise. This probably points to a need for more robust evidence in support of these recommendations which were issued on Level 3 evidence.

Studies showing an alarmingly high incidence of BE after SG in the long-term [12, 15, 16] show roughly the same incidence of intestinal metaplasia that is seen at the Gastro-Esophageal Junction (GEJ) [17] and have therefore been criticized [18] for not accounting for migration of the GEJ and cardia proximally into the thorax following SG. This is probably the reason that the committee agreed with an overwhelming 96.3% consensus that “studies investigating BE after SG should account for migration of the GEJ and gastric cardia (where intestinal metaplasia is very common) into the chest following SG”. Though a majority of the committee members (67.9%) felt that SG does not increase the risk of gastroesophageal junctional adenocarcinoma, this statement did not reach consensus even after two rounds of voting. It would, therefore, be prudent to keep an open mind on this topic and this may be why the committee agreed with 81.1% consensus that “SG patients should undergo a screening endoscopy every 5 years after surgery to screen for BE”.

Management of complications and revisional bariatric surgery can be two particularly challenging areas for surgeons. It was, therefore, very helpful that the committee was able to reach a consensus on most of these issues. Unsurprisingly perhaps, Re-sleeve did not reach a consensus as long-term data in its support is still lacking.

**Strengths and Weaknesses:**

This consensus-building exercise included 54 bariatric surgeons with significant experience and credentials. These surgeons are recognized leaders in the field and include the current, the incumbent, and several past presidents of International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO); editors in chief of two most prestigious journals in the field of obesity surgery – i.e., "Obesity Surgery" and "Surgery for Obesity and Related Diseases"; presidents or other office-bearers of many national obesity surgery societies; and many other surgeons recognized for academic excellence in the field. The exercise can, therefore, genuinely be regarded as a consensus amongst experts. Moreover, a representation of 32 countries means that this consensus statement can genuinely be regarded as a global effort. We, therefore, feel it will reduce variations in global practices concerning SG [11] and nudge individual practitioners towards consensus expert opinion. This should improve clinical outcomes with SG as well as help identify priority areas for future research.

Several weaknesses of this paper need to be emphasized. The choice of experts and the threshold of 70% for consensus have to be regarded as arbitrary. At the same time, as explained above, we genuinely feel a better-quality group would be difficult to assemble. The threshold of 70% has been used in several consensus-building exercises in the field of bariatric surgery and elsewhere [6-7]. Authors, therefore, feel it to be an appropriate cut-off. Understandably, a consensus agreement of a large number of experts would be regarded as stronger evidence than the opinion of a single expert. But it is still an opinion that needs confirmation in adequately designed studies. In that sense, consensus statements are only meant to guide current practice while the evidence develops; and should not be considered as a replacement for high-quality evidence.

**Conclusion:**

Fifty-four recognized opinion makers in the field of bariatric surgery from 32 countries around the world took part in this consensus statement on SG. Experts voted on a range of statements concerning various preoperative, perioperative, postoperative and complication management and revisional surgery considerations concerning SG. The findings of this paper will provide individual surgeons with much-needed clarity on a range of issues and also guide future research.

**Conflict of Interest Statement:**

Dr Ali Aminian received grants from Medtronic.

Dr Jacques Himpens receives consultancy fees from Ethicon and Medtronic.

Dr Jaime Ponce receives consultancy fees from Ethicon, Reshape Life sciences, Applied Medical and Allurion and payments for lectures from Gore and Olympus.

Prof. Jose M Balibrea received consultancy fees and payments for lectures from Johnson and Johnson and expert testimony from Beckton Dickinson.

Dr Kiron Bhatia receives ongoing consultancy fees from Apollo endo-surgery.

Dr Laurent Biertho received consultancy fees from Bausch and Novo Nordisk in addition to ongoing grants from Johnson and Jonson and Medtronic.

Dr Marina Kurian receives payments from Medtronic for lectures including speaking and teaching.

Prof. Peterli Ralph receives consultancy fees and grants

Prof. Gerhard Prager receives payments for the development of educational presentations from Medtronic.

Prof. Scott Shikora receives consultancy fees from Medtronic and Baxter and is employed by Springer Publishing as editor-in-chief of Obesity Surgery journal.

The other authors have no conflicts of interest or financial ties to disclose

**Statement of Human and Animal Rights:** Not Applicable

**Statement of Informed Consent:** Not Applicable

**Author Contribution:** Author 1 conceived the idea for this exercise, moderated it, analyzed the results, and wrote large sections of the manuscript. All other authors helped with determining the methodology of the exercise, provided feedback at every stage, took part in the online voting, critically reviewed the draft of the manuscript, and provided robust leadership. All authors have seen the final draft and approve of it.

**References:**

1. Angrisani L, Santonicola A, Iovino P, Vitiello A, Higa K, Himpens J, Buchwald H, Scopinaro N. [IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures.](https://www.ncbi.nlm.nih.gov/pubmed/30121858) Obes Surg 2018; 28(12): 3783-3794.
2. Gagner M, Hutchinson C, Rosenthal R. Fifth International Consensus Conference: current status of sleeve gastrectomy. Surg Obes Relat Dis 2016; 12(4): 750-756.
3. Adil MT, Aminian A, Bhasker AG, et al. Perioperative Practices Concerning Sleeve Gastrectomy - a Survey of 863 Surgeons with a Cumulative Experience of 520,230 Procedures. Obes Surg. 2020; 30(2): 483–492.
4. <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/> Last accessed on 23rd April’ 2020
5. <https://www.rand.org/topics/delphi-method.html> Last accessed on 23rd April’ 2020
6. Mahawar KK, Himpens J, Shikora SA, et al. The First Consensus Statement on One Anastomosis/Mini Gastric Bypass (OAGB/MGB) Using a Modified Delphi Approach. Obes Surg 2018; 28(2): 303-312.
7. Mahawar KK, Himpens JM, Shikora SA, et al. The first consensus statement on revisional bariatric surgery using a modified Delphi approach. Surg Endosc. 2020; 34(4): 1648–1657.
8. Mahawar KK, Aggarwal S, Carr WR, Jennings N, Balupuri S, Small PK. Consensus statements and bariatric surgery. Obes Surg. 2015; 25(6): 1063-5.
9. Sharples AJ, Mahawar K. Systematic Review and Meta-Analysis of Randomised Controlled Trials Comparing Long-Term Outcomes of Roux-En-Y Gastric Bypass and Sleeve Gastrectomy. Obes Surg 2020; 30(2): 664–672.
10. Navarini D, Madalosso CAS, Tognon AP, Fornari F, Barão FR, Gurski RR. Predictive Factors of Gastroesophageal Reflux Disease in Bariatric Surgery: a Controlled Trial Comparing Sleeve Gastrectomy with Gastric Bypass. Obes Surg 2020; 30(4): 1360‐1367.
11. Adil MT, Al-Taan O, Rashid F, et al. A Systematic Review and Meta-Analysis of the Effect of Roux-en-Y Gastric Bypass on Barrett's Esophagus. Obes Surg 2019; 29(11): 3712‐3721.
12. Felsenreich DM, Ladinig LM, Beckerhinn P, et al. Update: 10 Years of Sleeve Gastrectomy-the First 103 Patients. Obes Surg. 2018;28(11):3586‐3594.
13. McGlone ER, Gupta AK, Reddy M, Khan OA. Antral resection versus antral preservation during laparoscopic sleeve gastrectomy for severe obesity: Systematic review and meta-analysis. Surg Obes Relat Dis 2018; 14(6): 857‐864.
14. Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring) 2020; 28(4):
15. Sebastianelli L, Benois M, Vanbiervliet G, et al. Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett's Esophagus: Results of a Multicenter Study. Obes Surg. 2019;29(5):1462‐1469. doi:10.1007/s11695-019-03704-y
16. Genco A, Soricelli E, Casella G, et al. Gastroesophageal reflux disease and Barrett's esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication. Surg Obes Relat Dis. 2017;13(4):568‐574. doi:10.1016/j.soard.2016.11.029
17. Byrne JP, Bhatnagar S, Hamid B, Armstrong GR, Attwood SE. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol. 1999;94(1):98‐103. doi:10.1111/j.1572-0241.1999.00778.x
18. Mahawar KK, Carr WRJ, Borg CM, Aminian A. Does Sleeve Gastrectomy Cause Barrett's Oesophagus? Obes Surg 2018; 28(12): 4049‐4050.

**Abbreviations:**

**SG:** Sleeve Gastrectomy

**GERD:** Gastro-Esophageal Reflux Disease

**BE:** Barrett’s Esophagus

**GEJ:** Gastro-Esophageal Junction

**IFSO:** International Federation for the Surgery of Obesity and Metabolic Disorders